The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

If you're focused on delivering a high return on capital for your shareholders, you should consider M&A as an integral part ...

The Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) advanced 1.25% and 1.32%, respectively, in Q3 ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Health-care companies fell after disappointing earnings from one health insurer. Shares of Humana slid after the health-insurance firm warned of falling Medicare Advantage membership, and hinted that ...

Hearst Television's National Investigative Unit is learning more about a substance, not considered an opioid, being mixed ...